Ads
related to: chewable tablet for asthma treatment- Getting Started
Learn More About Dosing Schedules
Find Answers To Your Questions
- Register For A Webinar
Learn From Medical Professionals
Hear From Real Patients Like You
- Getting Started
Search results
Results From The WOW.Com Content Network
Montelukast, sold under the brand name Singulair among others, is a medication used in the maintenance treatment of asthma. [6] It is generally less preferred for this use than inhaled corticosteroids. [6] It is not useful for acute asthma attacks. [6] Other uses include allergic rhinitis and hives of long duration. [6]
An anti-asthmatic agent, also known as an anti-asthma drug, refers to a drug that can aid in airway smooth muscle dilation to allow normal breathing during an asthma attack or reduce inflammation on the airway to decrease airway resistance for asthmatic patients, or both. The goal of asthmatic agents is to reduce asthma exacerbation frequencies ...
Treat an asthma attack by visiting the hospital. Every year, more than 1.6 million Americans wind up in the emergency room because of an asthma attack, according to the CDC.If your attack is so ...
Zafirlukast is FDA-approved for the prevention and treatment of asthma in adults and children older than 5 years old. [1] Like other leukotriene receptor antagonists, zafirlukast is thought to be useful for the long-term treatment of asthma, but it is generally less effective than inhaled glucocorticoids as monotherapy (which are the standard of care) or long-acting beta-2 agonists in ...
Anti-asthmatic agents, also known as anti-asthma drugs, refer to drugs that can aid in airway smooth muscle dilation to allow normal breathing during an asthma attack or reduce inflammation on the airway to decrease airway resistance for asthmatic patients, or both. The goal of asthmatic agents is to reduce asthma exacerbation frequencies and ...
Dexpramipexole is a first-in-class oral investigational medicine that lowers blood and tissue eosinophils before they can cause damage in the target organ. Dexpramipexole is being developed by Areteia Therapeutics and has the potential to be the first oral treatment ever approved for eosinophilic asthma.
Ads
related to: chewable tablet for asthma treatment